Report Details:
15 Companies Covered
90 Pages
Antipsychotic Drugs Market Highlights
Antipsychotic Drugs Market size was valued at USD 17.49 Billion in 2024, and the market is projected to grow from USD 18.83 Billion in 2025 to USD 39.32 Billion by 2035, registering a CAGR of 7.64% during the forecast period 2025–2035.
MRFR recognizes the following companies as the key players in the Global Antipsychotic Drugs Market — H. Lundbeck A/S, Novartis, Acadia Pharmaceuticals, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Mylan, Boehringer Ingelheim, Pfizer, Janssen Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Roche, Otsuka Pharmaceutical, Lundbeck, and AbbVie.
The market growth is driven by rising mental health awareness, increasing prevalence of conditions such as schizophrenia and bipolar disorder, and advancements in drug formulations, including long-acting injectables. Governments and healthcare organizations are prioritizing mental health and implementing policies that support treatment accessibility and affordability, leading to improved adoption of antipsychotic therapies. Increasing investment in research and development is expected to bring innovative, personalized drugs with improved safety and efficacy to the market.
Long-acting injectable antipsychotics continue to gain traction due to better treatment adherence and outcomes for chronic mental health patients. Telehealth services have broadened access to psychiatric care, encouraging individuals to seek medical support from remote locations. The growing shift toward generics and the development of novel delivery methods further support market expansion throughout the forecast period.
Segment Analysis
The Antipsychotic Drugs Market has been segmented based on Drug Type, Indication, Administration Route, Patient Age Group, and Region.
Based on Drug Type, the market has been segmented into Typical Antipsychotics, Atypical Antipsychotics, Long-acting Injectables, and Mood Stabilizers. Among these, the Atypical Antipsychotics segment is projected to dominate the Global Antipsychotic Drugs Market revenue through the projected period due to their enhanced tolerability and reduced side effects.
Based on Indication, the market has been segmented into Schizophrenia, Bipolar Disorder, Major Depressive Disorder, and Autism Spectrum Disorders. Among these, the Schizophrenia segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Based on Route, the market has been segmented into Oral, Injectable, Transdermal. Among these, the Oral segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Based on Patient Age Group, the market has been segmented into Pediatric, Adult, Geriatric. Among these, the Adult segment is projected to dominate the market during the forecast period due to its high prevalence and increasing diagnosis rates.
Region Analysis
By Region, the Antipsychotic Drugs market is segmented into North America, Europe, Asia Pacific, South America and the Middle East & Africa. The North America Antipsychotic Drugs market holds a considerable market share and is also forecasted to hold the largest share during the forecast period. Increased awareness of mental health, strong healthcare infrastructure, and supportive reimbursement systems are key contributing factors. Europe follows closely with significant demand for advanced psychiatric treatments. Asia Pacific is expected to grow steadily due to rising healthcare expenditure and expanding access to mental health services.
Key Findings of the Study
- Adults accounted for an estimated 72% of the patient population in 2024, reflecting the high prevalence and increasing diagnosis of anxiety disorders worldwide.
- Digital mental healthcare continues accelerating, supported by growing internet penetration, AI-enabled treatment platforms, and expanding teletherapy adoption, improving access for millions of patients globally.
- North America accounted for 44.32% of the global market revenue in 2024.
- Europe represented the second-largest regional market, valued at approximately USD 1.90 billion in 2024, accounting for nearly 30% of global revenue.
